导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.30% | 2274/4773 |
| 近一周 | -3.99% | 4765/5462 |
| 近一月 | -11.39% | 5341/5421 |
| 近一季 | -22.20% | 5110/5209 |
| 近半年 | -2.40% | 1887/4920 |
| 近一年 | 5.51% | 1586/4366 |
| 近两年 | 126.44% | 355/2954 |
| 近三年 | 81.29% | 217/2253 |
| 成立以来 | 55.47% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.37% 2265/4961 |
39.05% 826/5312 |
- - |
- - |
| 2025 | 58.53% 249/4813 |
-3.50% 3056/3635 |
4.07% 871/4076 |
59.20% 133/4524 |
-0.84% 2677/4813 |
| 2024 | 21.97% 397/3463 |
-1.88% 1292/2808 |
-6.54% 1973/3014 |
33.44% 83/3129 |
-0.33% 1387/3463 |
| 2023 | -23.40% 1958/2656 |
-0.72% 1821/2280 |
-8.17% 1967/2385 |
-10.56% 2008/2515 |
-6.06% 1616/2655 |
| 2022 | -29.69% 1608/2207 |
-20.57% 1556/1919 |
6.88% 581/2016 |
-19.78% 1813/2113 |
3.25% 741/2208 |
| 2021 | 17.21% 240/1822 |
-6.55% 1015/1255 |
32.11% 33/1330 |
-6.51% 944/1466 |
1.55% 880/1822 |
| 2020 | 88.75% 25/1250 |
4.78% 60/1028 |
35.83% 17/1067 |
9.85% 608/1164 |
20.72% 61/1184 |
| 2019 | 51.18% 97/1092 |
34.84% 105/754 |
-10.30% 730/804 |
8.65% 61/850 |
15.05% 16/918 |
| 2018 | -37.52% 599/834 |
- - |
- - |
- - |
-14.37% 581/691 |
| 2017 | -14.81% 561/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华安创业板50ETF VS. 长安沪深300非周期A(740101) |